Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 14, 2026
Curis, Inc. (CRIS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $8.6 million. As of Jun 30, 2026 it held $5.1 million in cash and investments and $1.0 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-8.58M
+0.1% vs year-ago quarter
Operating cash flow
$-9.65M
-20.4% vs year-ago quarter
Free cash flow
—
EPS
$-4.02
+70.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.09M
-83.3% vs year-ago quarter
Net cash
$4.07M
Q2 FY2026
Operating margin
-203.2%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRIS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lexington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1108205
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.1M | $3.2M | $2.7M |
| Operating income | -$9.9M | -$11.5M | $19.6M | -$6.9M | -$8.3M |
| Net income | -$8.6M | -$24.2M | $19.4M | -$7.7M | -$8.6M |
| Diluted EPS | -$4.02 | -$1.25 | $1.23 | -$0.49 | -$13.61 |
| Operating cash flow | -$9.6M | -$9.0M | -$6.4M | -$5.6M | -$8.0M |
| Total assets | $19.0M | $29.7M | $20.0M | $27.6M | $29.2M |
| Total liabilities | $14.3M | $17.0M | $14.5M | $42.3M | $43.2M |
| Stockholders' equity | $4.7M | $12.7M | $5.5M | -$14.7M | -$14.0M |
| Cash and investments | $5.1M | $15.0M | $5.1M | $9.1M | $10.1M |
| Total debt | $1.0M | $1.3M | $1.6M | $9.0M | $9.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 30, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K/A |
Amended current report
Bylaw or fiscal year change
|
Jul 1, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jul 1, 2026 | Jun 25, 2026 |
All 1006 Curis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.